Wal-Mart, the world's largest retailer, has launched a pilot program in the US State of Florida to provide nearly 300 generic drugs to customers with or without medical insurance for $4 per month. For many customers who are insured, these prices will actually be lower than their co-payments.
The stock market's reaction to the news was a fall for major Wal-Mart competitors, including Walgreens and CVS. In response to the news, another leading US retailer, Target, announced that it would match Wal-Mart's offer.
Wal-Mart chief executive, H Lee Scott said: "competition and market forces have been absent from our health care system, and that has hurt working families tremendously." He added that the scheme will eventually be expanded across the country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze